In many randomized clinical trials of therapeutics for COVID-19, the primary outcome is an ordinal, categorical variable for which the final category is often death, which can be ascertained at the time of occurence. For the remaining categories, determination of into which of these categories a participant's outcome falls cannot be made until some ascertainment time that can be less than or equal to a pre-specified follow-up time. Interest focuses on the odds ratio (active agent vs. control) under the assumption of a proportional odds model. Although at the final analysis the outcome will be determined for all subjects, at an interim analysis, the status of some participants may not yet be determined; accordingly, the outcome from these subjects can be viewed as censored. A valid interim analysis can be based on data only from those subjects with full follow up; however, this approach is inefficient, as it does not exploit additional information that may be available on those who have not reached the follow-up time at the time of the interim analysis. Appealing to the theory of semiparametrics, we propose an estimator for the odds ratio in a proportional odds model with censored, time-lagged categorical outcome that incorporates such additional baseline and time-dependent information and demonstrate that it can result in considerable gains in efficiency relative to simpler approaches.
翻译:在对COVID-19治疗方法的许多随机临床试验中,主要结果是一个极直截了当的变量,最终类别往往是死亡,在出现时可以确定;对于其余类别,只有在确定时间少于或等于事先规定的后续行动时间之后,才能确定参与者结果属于哪些类别; 利息的重点是假设比例差数比(活性剂对控制),假设比例差数模型。 虽然在最后分析时,将确定所有科目的结果,但在临时分析中,一些参加者的地位可能尚未确定;因此,可以将这些主题的结果视为审查的结果; 有效的临时分析只能以那些主题的数据为基础,并全面跟踪; 然而,这种办法效率低,因为它没有利用在临时分析时尚未达到后续行动时间的那些人可能掌握的额外信息(活性剂对控制)。